 | Up a level |
Radojewski, Piotr; Dumont, Rebecca; Marincek, Nicolas; Brunner, Philippe; Mäcke, Helmut R; Müller-Brand, Jan; Briel, Matthias; Walter, Martin Alexander (2015). Towards tailored radiopeptide therapy. European journal of nuclear medicine and molecular imaging, 42(8), pp. 1231-1237. Springer 10.1007/s00259-015-3030-9
Wicki, Andreas; Wild, Damian; Prêtre, Vincent; Mansi, Rosalba; Orleth, Annette; Reubi, Jean-Claude; Rochlitz, Christoph; Mamot, Christoph; Mäcke, Helmut R; Christofori, Gerhard (2014). Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors. EJNMMI research, 4(1), p. 9. Springer 10.1186/2191-219X-4-9
Villard, Linda; Romer, Anna; Marincek, Nicolas; Brunner, Philippe; Koller, Michael T; Schindler, Christian; Ng, Quinn K T; Mäcke, Helmut R; Müller-Brand, Jan; Rochlitz, Christoph; Briel, Matthias; Walter, Martin A (2012). Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. Journal of clinical oncology, 30(10), pp. 1100-6. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2011.37.2151
Imhof, Anna; Brunner, Philippe; Marincek, Nicolas; Briel, Matthias; Schindler, Christian; Rasch, Helmut; Mäcke, Helmut R; Rochlitz, Christoph; Müller-Brand, Jan; Walter, Martin A (2011). Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of clinical oncology, 29(17), pp. 2416-23. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2010.33.7873
Cescato, Renzo; Loesch, Kimberly A; Waser, Beatrice; Mäcke, Helmut R; Rivier, Jean E; Reubi, Jean-Claude; Schonbrunn, Agnes (2010). Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Molecular endocrinology, 24(1), pp. 240-9. Bethesda, Md.: Endocrine Society 10.1210/me.2009-0321
Wicki, Andreas; Wild, Damian; Storch, Daniel; Seemayer, Christian; Gotthardt, Martin; Behe, Martin; Kneifel, Stefan; Mihatsch, Michael J; Reubi, Jean-Claude; Mäcke, Helmut R; Christofori, Gerhard (2007). [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clinical cancer research, 13(12), pp. 3696-705. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-06-2965
Wild, Damian; Béhé, Martin; Wicki, Andreas; Storch, Daniel; Waser, Beatrice; Gotthardt, Martin; Keil, Boris; Christofori, Gerhard; Reubi, Jean Claude; Mäcke, Helmut R (2006). [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. Journal of nuclear medicine, 47(12), pp. 2025-33. New York, N.Y.: Society of Nuclear Medicine
Ginj, Mihaela; Zhang, Hanwen; Waser, Beatrice; Cescato, Renzo; Wild, Damian; Wang, Xuejuan; Erchegyi, Judit; Rivier, Jean; Mäcke, Helmut R; Reubi, Jean Claude (2006). Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proceedings of the National Academy of Sciences of the United States of America - PNAS, 103(44), pp. 16436-41. Washington, D.C.: National Academy of Sciences NAS 10.1073/pnas.0607761103
